United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $379.6923.
Several equities research analysts recently issued reports on the company. Bank of America cut their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Cantor Fitzgerald assumed coverage on United Therapeutics in a research note on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target for the company. Morgan Stanley cut their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Finally, UBS Group cut their price target on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research note on Monday, June 30th.
Get Our Latest Stock Report on United Therapeutics
United Therapeutics Stock Down 0.4%
Shares of NASDAQ:UTHR opened at $300.43 on Tuesday. United Therapeutics has a 12-month low of $266.98 and a 12-month high of $417.82. The stock has a market cap of $13.55 billion, a PE ratio of 11.73, a P/E/G ratio of 4.57 and a beta of 0.57. The business has a 50 day moving average of $296.14 and a 200-day moving average of $310.09.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The firm had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter in the prior year, the firm earned $5.85 EPS. The company's revenue was up 11.7% on a year-over-year basis. Equities research analysts expect that United Therapeutics will post 24.48 earnings per share for the current year.
Insider Activity
In other news, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the transaction, the chief financial officer directly owned 8,118 shares in the company, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nilda Mesa sold 645 shares of the company's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director owned 4,883 shares of the company's stock, valued at $1,416,021.17. This trade represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,681 shares of company stock valued at $24,618,359 in the last three months. Company insiders own 10.30% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of UTHR. XTX Topco Ltd acquired a new stake in United Therapeutics in the first quarter valued at $313,000. Allianz Asset Management GmbH increased its holdings in United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after purchasing an additional 33,254 shares during the period. Cerity Partners LLC increased its holdings in United Therapeutics by 30.4% in the fourth quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after purchasing an additional 2,702 shares during the period. LPL Financial LLC increased its holdings in United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after purchasing an additional 11,007 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in United Therapeutics by 11.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.